September 24, 2008

l‐Ornithine‐l‐aspartate in the management of hepatic encephalopathy: A meta‐analysis

Key Points

Key points are not available for this paper at this time.

Abstract

LOLA benefited patients with overt hepatic encephalopathy (I or II), whereas these data do not support the use of LOLA for patients with subclinical hepatic encephalopathy.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Jiang et al. (Wed,) studied this question.

synapsesocial.com/papers/69d80bfca2a48916bbbeeb57 — DOI: https://doi.org/10.1111/j.1440-1746.2008.05582.x

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study· 2006 · 98 citations
Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial.· 1977 · 649 citations
Hepatic encephalopathy· 2001 · 61 citations
Hepatology: A Textbook of Liver Disease· 1997 · 391 citations
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?· 1996 · 17,690 citations

Authors

Qian Jiang

Yantai University

Xuehua Jiang

Ming‐Hua Zheng

Wenzhou Medical University

Journals

Journal of Gastroenterology and Hepatology

Actions

Institutions

Sichuan University

Wenzhou Medical University

First Affiliated Hospital of Wenzhou Medical University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

l‐Ornithine‐l‐aspartate in the management of hepatic encephalopathy: A meta‐analysis

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Also consider